×

RNS Number : 2179A

ValiRx PLC

28 September 2020

 

28 September 2020

 

("ValiRx", the "Company" or the "Group")

VAL201 Clinical Trial Update 

Headline results demonstrate VAL201 has potential to be a safe and well-tolerated drug

London, UK ValiRx (AIM:VAL) reports today that it has received headline results from the recently completed Phase 1/2 clinical trial of its lead asset VAL201, for the treatment of advanced prostate cancer, held at University College Hospital (UCLH), London.

The headline results, detailed below, provide a summary of the top-level data of safety and tolerability as well as evidence for disease impact as observed during the clinical trial.  Full data and details of from the clinical trial are expected to be received by the Company by end Q4 2020.

Disease Impact – Overall Response Rate 54.5%

Evidence for positive disease impact has been measured using PCWG2 (Prostate Cancer Working Group 2) guidelines.  These industry standard guidelines take into account both the primary tumour and metastatic tumours alongside prostate specific antigen (PSA) levels to assess whether the disease has progressed, or whether the patient has responded and halted disease progression.  These guidelines provide a more comprehensive measure of disease impact than just primary tumour imaging.

Of the 12 patients dosed with VAL201, 11 patients had sufficient PCWG2-relevant data collected across multiple cycles. 6 of these 11 have been categorised as responding throughout treatment.  That is, when the treatment with VAL201 was halted for a defined reason, whether or not the 6 standard cycles had been completed, these patients showed no disease progression by PCWG2 criteria with stable disease.

Safety and Tolerability – no Maximum Tolerated Dose declared

As the first clinical trial of VAL201, safety and tolerability data are of paramount importance. 

The headline safety and tolerability results demonstrated only one dose-limiting toxicity event occurred.  This was at a maximum dose of 8 mg/kg, with the patient having raised blood pressure (severe hypertension).   Following treatment for the raised blood pressure, the patient completed the remainder of the trial.

A Maximum Tolerated Dose has not been determined for VAL201, and all doses remain available for further testing.

No deaths were reported in patients during the clinical trial.

Further minor events listed as likely to be related to the administration of VAL201 are: Injection site disorders in 11 out of 12 patients; fatigue (5/12); dyspepsia (1/12); muscle spasm (1/12); hypertension (2/12); bradycardia (1/12).

Next Steps

During Q4 2020, the Company expects to receive the full Clinical Study Report and will use the complete data to publish the results on the National Institute of Health's (NIH) public database ClinicalTrials.gov, as well as to produce research papers for peer-reviewed publications.

The Company intends to share these results with potential industry partners to evaluate all options for further clinical development of VAL201.

Dr Suzy Dilly, Chief Executive Officer commented: "I am delighted to be able to share these exciting results today, which are an accumulation of a lot of work by the wider team, both within and external to ValiRx.  While considering these results it is important to remember that this is only the first clinical trial using VAL201, so this data has been generated using the utmost caution in sequentially dosing patients.  Nevertheless, the headline results clearly demonstrate that VAL201 has the potential to be a safe and well-tolerated drug.  With this data in hand, future studies will investigate optimal dosing strategies for VAL201 and help confirm these early indications of a positive response rate."

Professor Alan Boyd, Consultant Pharmaceutical Physician and Medical Monitor for the study commented: "Development of effective treatments with low-side effects for patients with prostate cancer who have relapsed after radiotherapy is essential and will improve the lives of patients during treatment.  I am pleased to have contributed to a project that has demonstrated such a good safety and tolerability profile while giving the first indications of a favourable effect on the patient's disease." 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

For further information please contact:

 

ValiRx plc	Tel: +44 (0) 20 7073 2628 www.valirx.com
Suzanne Dilly	[email protected]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880
Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker	Tel: +44 (0) 20 7469 0930
Optimum Strategic Communications Supriya Mathur/ Shabnam Bashir	Tel: +44 (0) 20 8148 3040 [email protected]

 

 

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework to enable rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the promise of achieving a more streamlined, less costly, drug development process.  We work closely with our selected collaborators and leverage the combined expertise required for science to advance. 

Lead candidates from our portfolio are out-licenced or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

About VAL201

VAL201 is a short peptide being studied for the treatment of prostate cancer. The peptide structure is inspired by the naturally occurring androgen receptor, and is designed to intercept and prevent the binding of the androgen receptor to SRC kinase – an enzyme implicated in cancerous cell growth pathways. By preventing the androgen-mediated activation of SRC kinase, VAL201 can potentially prevent cancerous cell proliferation (or growth) without interfering with other functions of either the androgen receptor or SRC kinase. This precision method, mimicking a natural process, proposes a high specificity of cancer treatment with a lower side effect profile. VAL201 was licensed from CRT (part of CRUK) in 2010 and developed through preclinical development into this clinical trial in patients with advanced prostate cancer. The study was held at University College Hospital (UCLH), London.

About the VAL201-001 clinical trial

The clinical trial: "A Phase I/II, Dose Escalation Study to Assess the Safety and Tolerability of VAL201 in Patients with locally Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours" opened to recruitment in December 2014 and closed in January 2020.

Patients were scheduled for treatment of a once weekly injection of VAL201 in 3 week cycles for a maximum of 6 cycles.  A total of 12 patients received at least 1 dose of VAL201.

Patients were eligible if they were: Adult men (over the age of 18) with incurable locally advanced or metastatic prostate cancer who had relapsed following radiotherapy treatment, are in 'watchful waiting' or where a policy of intermittent hormone therapy had been decided.  Patients were expected to have no or only mild symptoms relating to their prostate cancer. (ClinicalTrials.gov identifier: NCT02280317)

About Prostate Cancer

Around 48,500 men are diagnosed with prostate cancer in the UK each year[1]. In men, it is the most common cancer in the UK.  Prostate cancer is most common in older men. On average each year 35 out of 100 (35%) of new cases are in men aged 75 and over.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.

Factors that could cause actual results to differ materially from those in the forward-looking statements include risks relating to unanticipated costs, liabilities or delays; failure or delays in research and development programs; the safety and efficacy of the Company's product candidates and the likelihood of clinical data to be positive and of such product candidates to be approved by the applicable regulatory authorities; unanticipated changes relating to competitive factors in the Company's industry; risks relating to the Company's capitalisation, resources and ownership structure, the availability of sufficient resources for company operations and to conduct or continue planned clinical development programs; the outcome of any legal proceedings; risks related to the ability to correctly estimate operating expenses; risks related to the ability to project future cash utilisation and reserves needed for contingent future liabilities and business operations; risks related to the changes in market prices of the Company's ordinary shares; the Company's ability to hire and retain key personnel; changes in law or regulations affecting the Company; international, national or local economic, social or political conditions that could adversely affect the Company and its business; conditions in the credit markets; risks associated with assumptions the Company makes in connection with its critical accounting estimates and other judgments.

 

Ends

 

 

---

[1] https://www.cancerresearchuk.org/about-cancer/prostate-cancer/about

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCPPUBWBUPUGMM

Close

×

RNS Number : 6544Z

Incanthera PLC

22 September 2020

 

 

 

22 September 2020

 

Incanthera plc

 

("Incanthera" or the "Company")

 

Sol Skin Cancer Technology

 

Successful Results of Permeation Study

 

Incanthera plc (AQSE: INC), the specialist oncology company focused on transforming cancer treatment, is pleased to announce successful study results for its skin cancer technology, Sol.

 

Highlights

 

Sol is a proprietary topical formulation designed to deliver into the skin an active known to prevent the conversion of solar (actinic) keratoses into skin cancer.

 

· A new refined formulation of Sol demonstrates statistically significant greater dermal delivery compared with four known comparator products

· Confirmation of exceeding bioequivalence compared with oral delivery

 

The study, run by the University College of London, School of Pharmacy ("SoP"), has demonstrated that Sol affords greater permeation (delivery of the active into the skin) than comparator products.

 

The study, undertaken over the past few months, was conducted with the aim of comparing the permeability profile of a new refined formulation of Sol against a panel of four known comparator products. The comparator products comprised formulations that contain the same active ingredient over a range of concentrations, with the expectation of delivering the active through the skin for use in other general cosmetic applications.

 

The results demonstrated that Sol delivered a greater permeation of the active compared to all four assessed commercial products and that difference was statistically significant (p<0.05 at 24h).

 

In a previous study (Summer 2019), using an identical model of human skin penetration, the results demonstrated that the delivery of the active with Sol exceeded bioequivalence when compared with oral dosing of the same active. The new data from the current study confirm that this new refined formulation of Sol also exceeds bioequivalence.

 

These results have exceeded the Company's expectations, demonstrating unequivocally the efficacy of Sol's formulation in penetrating the skin barrier and reaching the deeper layers where an effective prevention of skin cancer could be achieved.

 

The Company is delighted with not only the confirmation of Sol's superior formulation technology capabilities against non-proprietary creams, but also the strength of the data received, which further enhances the data package to potential commercial partners.

 

These results follow the filing in July 2020 of a new patent protecting Sol for the prevention and treatment of solar keratoses and related cancers of the skin, which if granted, will further extend the life of the patent family protecting Sol to 2041.

 

 

Commenting on the results of the study, Chairman, Tim McCarthy said:

 

"We are delighted at demonstrating the clear efficacy advantage that Sol has when compared to other approaches at delivering the active ingredient into and across the dermal barrier.

 

The level at which the performance of this patented technology has exceeded expectations is extremely encouraging. This is an important step to enable us to move forward negotiations with potential commercial partners."

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

The directors of the Company take responsibility for this announcement.

 

For further enquiries:

 

Incanthera plc www.incanthera.com   Tim McCarthy, Chairman [email protected]   Simon Ward, Chief Executive Officer [email protected]   Suzanne Brocks, Head of Communications [email protected]	+44 (0) 7831 675747     +44 (0) 7747 625506     +44 (0) 7776 234600
Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Jo Turner/James Lewis	+44 (0) 20 7213 0880
Broker: Stanford Capital Partners Ltd Patrick Claridge/John Howes/Bob Pountney	+44 (0) 20 3815 8880

 

 

Notes to Editors:

 

Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

 

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers.

 

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

 

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

 

For more information on the Company please visit: www.incanthera.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXKKDBQBBKBFCB

Close

×

Neville Registrars is delighted to welcome S-Ventures PLC as the newest addition to its list of client companies.

S-Ventures is an investment company listed on the AQUIS Exchange specialising in the natural and organic consumer sectors.

Further information can be found on the Company's website: https://s-venturesplc.com/

Close

×

RNS Number : 8226Y

N4 Pharma PLC

14 September 2020

 

14 September 2020

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

Covid-19 Proof of Concept Update and move to in vivo study

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing, a novel delivery system for cancer treatments and vaccines, provides an update on its Covid-19 proof of concept work utilising Nuvec® loaded with Coronavirus plasmid.

As announced on 12 August 2020, stage 2 of the proof of concept work was successfully completed with the transfection of HEK (Human Embryonic Kidney) cells of Nuvec® loaded with Coronavirus plasmid in vitro. Following the completion of stage 3 of the proof of concept work and a review of the results, the Company is continuing to explore the utility of Nuvec® with the Coronavirus plasmid and will progress to an in vivo study in due course.

 

Whilst the single intradermal injection used in the stage 3 pre (pilot) in vivo study did not result in a measurable expression of the spike protein in the target cells of the murine target, neither did the positive control. Additional exploratory studies will continue to understand the translation potency of the Coronavirus plasmid including optimisation of Nuvec® plasmid loading. With this in mind and taken together with previous positive data, the Company has decided to proceed to a full in vivo study to demonstrate the capability of Nuvec® to generate Covid-19 specific antibodies.

 

The Company is in the process of scoping the programme of studies required.

 

Nigel Theobald, Chief Executive Officer, commented: "The initial pilot work of stage 3 of the Covid-19 proof of concept work was narrow in its scope and, having reviewed the results, we have taken the decision to move to a full in vivo study to establish an immune response through the production of antibodies. In undertaking the work we aim to demonstrate Nuvec®'s capabilities both as a potential delivery technology for multiple vaccines as well as for Covid-19 specifically. I look forward to providing further updates in due course."

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

 

Enquiries:

 

N4 Pharma plc
Nigel Theobald, CEO	Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP	Tel: +44(0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited	Tel: +44(0)20 3657 0050
Joint Broker
Andy Thacker
IFC Advisory Ltd Financial PR Graham Herring Zach Cohen	Tel: +44(0)20 3934 6630

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

UPDKXLFFBKLXBBB

Close

×

RNS Number : 5430Y

LoopUp Group PLC

10 September 2020

 

10 September 2020

LOOPUP GROUP PLC
("LoopUp Group" or the "Group")

 

LoopUp Contract Wins, Business Update & Notice of Interim Results

 

–  Major new contract win with one of the world's top-5 law firms

–  Expanded partnership to FY2022 with C&W Communications

–  Launch of new online plans for LoopUp Meetings

 

LoopUp Group plc (LSE AIM: LOOP), the premium cloud communications provider, is pleased to provide the following business update and notice of its upcoming interim results for the period ended 30 June 2020 on Wednesday 23 September 2020.

 

Major Customer Wins:

The Group is pleased to announce that it has signed a significant new contract with one of the world's top-5 law firms. Following a successful pilot with 300 users, LoopUp Meetings will now be rolled out globally with the potential to become one of the Group's largest accounts.

 

This contract follows two other top-100 global law firm wins secured during July and August 2020, demonstrating LoopUp's continued success to expand its footprint in the Professional Services market.

 

Partnership expansion with Cable & Wireless:

LoopUp has also successfully expanded its existing partnership with C&W Communications, one of the leading telecommunications providers in the Caribbean and Latin America, in a new contract which will run through to the end of FY2022.

 

'Conferencing on Demand', powered by LoopUp – a white-labelled version of LoopUp Meetings – will now be included in C&W's core Unified Communications and Collaboration portfolio of products, with expanded distribution across 16 countries: Anguilla, Antigua & Barbuda, Bahamas, Barbados, British Virgin Islands, Cayman Islands, Dominica, Grenada, Jamaica, Montserrat, Saint Kitts and Nevis, Saint Lucia, Saint Vincent & the Grenadines, Turks & Caicos, Trinidad & Tobago, and later this year, Panama.

 

This expanded partnership also involves the internal deployment of LoopUp Meetings as another advanced conferencing tool for C&W's own internal corporate use.

 

Launched new online plans for LoopUp Meetings:

The Group has launched two new online plans for LoopUp Meetings to promote lead generation via the product's established network effect. These new offerings are aimed at individual users within target market professional services firms, who experience the product as guests of existing customers, and who then wish to try out the product for hosting their own online meetings.

 

The Free Plan is restricted to domestic meetings via the LoopUp join link with a maximum of 10 guests. The Business Plan upgrade is charged at a promotional level of £15/$15/€15 per month, which then removes the Free Plan's restrictions.

 

This move provides an opportunity for more target market users to try out and experience LoopUp Meetings in a freemium model and for 'land-and-expand' new business in target market accounts.

 

 

Notice of interim results:

The Group will announce its interim results for the period ended 30 June 2020 on Wednesday 23 September 2020.

 

Steve Flavell and Michael Hughes, co-CEOs of LoopUp Group, commented:

 

"We are pleased to announce the Group has secured these important contract wins demonstrating the continued momentum at LoopUp. Great communications have always been at the heart of successful organisations, now more than ever. We are delighted to be chosen and relied on to provide simple and secure business-critical communications in these challenging times."

 

 

Market abuse regulation:

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

 

For further information, please contact:

LoopUp Group plc	via FTI
Steve Flavell, co-CEO
Panmure Gordon (UK) Limited	+44 (0) 20 7886 2500
Dominic Morley / Alina Vaskina (Corporate Finance)
Erik Anderson (Corporate Broking)
Numis Securities Limited	+44 (0) 20 7260 1000
Simon Willis / Jonny Abbott (Corporate Finance)
FTI Consulting, LLP	+44 (0) 20 3727 1000
Matt Dixon / Emma Hall / Jamille Smith / Shamma Kelly

 

About LoopUp Group plc:

LoopUp (LSE AIM: LOOP) is a premium cloud communications solution for business-critical external communications. The solution combines premium remote meetings with inbound and outbound cloud voice services via Direct Routing integration with Microsoft Teams. Our customers benefit from a global fully-managed service, and an emphasis on security, reliability and simplicity, delivered with deep domain expertise and caring customer support. We're proud to be trusted provider to over 5,000 organisations worldwide, including more than 20 of both the world's top-100 law firms and top-100 private equity firms, as well as enterprises such as Travelex, Kia Motors, Planet Hollywood and National Geographic. The Group is headquartered in London, with offices in San Francisco, New York, Boston, Chicago, Dallas, Los Angeles, Denver, Cardiff, Milton Keynes, Madrid, Berlin, Malmo, Hong Kong, Sydney and Barbados, and is listed on the AIM market of the London Stock Exchange (LOOP). For further information, please visit: www.loopup.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCBIGDCBSGDGGC

Close

×

RNS Number : 1408X

Biome Technologies PLC

26 August 2020

 

 

26 August 2020

Biome Technologies plc

("Biome", the "Group" or the "Company")

Biome Technologies plc wins a new grant of £273k to support scale-up of its novel compostable bioplastic materials

 

Biome announces that its Bioplastics division ( www.biomebioplastics.com ) has been awarded funding of £273,000 from the UK Government's Innovate UK to support a new £350,000 collaborative project to scale-up its novel compostable bioplastic materials with the University of Nottingham's Department of Chemical and Environmental Engineering.

In line with expanding Biome Bioplastics materials portfolio using novel technology, this funding will accelerate the testing of the commercial viability of the three most exciting candidate materials in the division's current research portfolio. This project will use microwave technology in the development of an efficient, industrially scalable manufacturing process and will conduct further larger scale testing at the Biorenewables Development Centre in York.

Since 2013, Biome's Bioplastics division has directed more than six million pounds of research and development funding, supported by various grants and in association with a number of leading UK universities, towards a new portfolio of bio-based and biodegradable materials. This work is focused on the replacement of aromatic co-polymers currently widely used in the market with a new generation of heteroaromatic polyesters, which have the potential for differentiated functional performance coupled with tailored biodegradation.

It is anticipated that this project will start in October 2020 and will be completed within two years.

Paul Mines, Biome Technologies' Chief Executive commented:

"This latest research project is an important enabling step in understanding the performance and functionality of Biome's most exciting novel polymers. We believe these materials could represent an important addition to the business's product range in due course and will bring benefits to manufacturers, consumers and the environment."

Derek Irvine, Professor of Materials Chemistry, Faculty of Engineering, University of Nottingham commented:

"Developing differentiated and commercially viable new products and processes, which have sustainability as a key focus, is one of our core interests and capabilities. We are excited to be working with Biome to apply our skills and knowledge to these interesting new sustainable polymers."

-Ends-

 

For further information please contact: Biome Technologies plc

Paul Mines, Chief Executive Officer

Donna Simpson-Strange, Company Secretary

[email protected]

Tel: +44 (0) 2380 867 100

www.biometechnologiesplc.com

 

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Kelly Gardiner (Broker)

Tel: +44 (0) 20 3328 5656

www.allenbycapital.com

 

About Biome

Biome Technologies plc is an AIM [BIOME] listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

The Group comprises two divisions, Biome Bioplastics Limited and Stanelco RF Technologies Limited.

Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil-based polymers.

Stanelco RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

 

www.biometechnologiesplc.com

www.biomebioplastics.com   and  www.thinkbioplastic.com  

www.stanelcorftechnologies.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.

 

END

 

 

NRAPPUQPRUPUGMA

Close

×

RNS Number : 8923W

Woodbois Limited

24 August 2020

 

24 August 2020

Woodbois Limited

("Woodbois", the "Group" or the "Company")

 

Top Three Ranking in SPOTT Transparency Assessment

 

Notice of Results

 

Woodbois Limited (AIM: WBI), the African focused forestry and timber trading company, is pleased to announce it has ranked 3rd in the Sustainability Policy Transparency Toolkit ('SPOTT'') ESG policy transparency assessments for the worldwide timber and pulp industries.

SPOTT, the online platform created by the Zoological Society of London ('ZSL'), annually assesses multiple worldwide timber and pulp producers and traders on the public disclosure of their policies, operations and commitments to Environmental, Social and Governance ("ESG") best practice.

 

The recognition of Woodbois' ESG practices and the transparency of our disclosures is a welcome endorsement of our practices, and further enhancing these high standards lies at the centre of management's goals on behalf of all stakeholders. Woodbois was recognised as the highest-ranked public company.

 

The Company welcomes the publication of assessments from bodies such as the ZSL and has made a number of commitments in its recently published Sustainability Report for 2019 to further align operating practices with specific UN Sustainable Development Goals.

 

As the importance of sustainable forestry management increasingly becomes a focal point in the mitigation of deforestation and climate change, Woodbois is dedicated to being at the forefront of transparency and best practice.

 

Chairman and CEO Paul Dolan said: "We are delighted to announce that, in only our second year of assessment, our ranking has improved to 3rd place out of 103 companies in the SPOTT timber producers table. We consistently strive to improve the standards of our ESG policies, providing transparency and good governance along with our sustainability focussed operating model. The recognition of this by SPOTT independently validates these policies and we have a secure foundation to build upon."

 

To see the SPOTT assessment for all 103 companies, please click here

To see Woodbois' 2019 Sustainability Report, please click  here

 

Notice of Results

 

The Company will announce its interim results for the six months to 30 June 2020 on Wednesday 2 September 2020.

 

 

Enquiries:

Woodbois Limited Paul Dolan – Chairman and CEO	+ 44 (0)20 7099 1940
Canaccord Genuity, Nominated Advisor and Broker Henry Fitzgerald-O'Connor James Asensio Thomas Diehl	+ 44 (0)20 7523 8000
Alma PR, Financial PR Rebecca Sanders-Hewett Justine James Robyn Fisher Kieran Breheny	+44 (0)20 3405 0205 [email protected]

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCKXLFLBVLFBBX

Close

×

RNS Number : 9814V

Panoply Holdings PLC (The)

13 August 2020

 

13 August 2020

 

The Panoply Holdings PLC

("The Panoply", or the "Group")

 

Significant contract wins

Two digital transformation projects to be delivered for HM Land Registry

 

The Panoply Holdings PLC, the technology-enabled services group focused on digital transformation, is pleased to announce two significant contracts signed with HM Land Registry by Group companies FutureGov and Notbinary.

 

The two contracts were awarded to FutureGov and Notbinary in response to separate bids placed on the Government's digital marketplace and are worth a value of up to £3.2m and £1.6m respectively. The contracts, which are already accounted for in the Board's forecasts, are expected to be up to 24 months long.

 

The Group's ability to secure these contracts validates the strength of its differentiated offering to the public sector and demonstrates the increasing scale and value of the projects it is now delivering.

 

FutureGov was selected over 25 other bids and will be the client's user-centred design research and capability partner within its digital and data transformation programme. Notbinary was selected over 36 other bids to become HM Land Registry's partner specialising in Product Management, helping to build knowledge and capability within the organisation in the delivery and transformation of digital service development and the continuous improvement of user centred land registration services.

 

These two projects demonstrate well the different types of opportunities available to the Group and which its two full stack brands: FutureGov and Foundry4 (which Notbinary now sits under), have been designed to address. FutureGov focuses on CEO/COO type economic buyers looking at digital transformation through the lens of organisational change and end-to-end service design including technology whereas Foundry4 is focused on CTO/CIOs looking to enable digital transformation through the adoption of hyper scale cloud, data analytics, machine learning and automation.

 

Neal Gandhi, CEO of The Panoply commented:

 

"To win both bids and secure contracts worth up to £4.8m shows that our approach of bringing together experts across the full spectrum of digital transformation services is resonating with clients. In this case, HM Land Registry know that they have world class experts in user centred design as well as product management yet in a single group that has proven its ability to work to bring those two work streams together as required to deliver an end to end service. 

 

This is our second contract win worth more than £4m so far this financial year and it is in addition to the £13m in new contract wins announced in the trading update issued on July 21 2020. The win gives us further confidence in our forecasts for the current financial year."

 

Enquiries:

The Panoply Holdings Neal Gandhi (CEO) Oliver Rigby (CFO)   Stifel Nicolaus Europe Limited (Nomad and Broker)   Via Alma PR     +44 (0)207 710 7600 Fred Walsh Alex Price       Alma PR (Financial PR) Susie Hudson Josh Royston Harriet Jackson [email protected] +44(0)203 405 0205

 

About The Panoply

 

The Panoply is a digitally native technology services company, built to service clients' digital transformation needs. Founded in 2016, with the aim of identifying and acquiring best-of-breed specialist information technology, design and innovation consulting businesses, the Group collaborates with its clients to deliver the technology outcomes they're looking for at the pace that they expect and demand.

The Group is being increasingly recognised as a leading alternative digital transformation provider to the UK public services sector, with c.70% of its client base representing the public sector and c.30% representing the commercial sector.

More information is available at www.thepanoply.co m

 

 

About FutureGov

FutureGov is a change agency, on a mission to build 21st-century public institutions that are catalysts for change in the internet and climate era.. Using digital tools and design approaches of the digital age, we support organisations through digital transformation and service design, building on the best of places to organise for change and radically improve outcomes for communities in the 21st century.

 

Find out more at www.wearefuturegov.com

 

About Foundry4

 

foundry4 is a fresh new transformation business that works with organisations to help them thrive in the digital economy. Connecting insights, design, technology and data we accelerate growth and deliver sustainable change.

 

Combining the extensive technology and experience capabilities of Notbinary and Arthurly with the deep industry insight of DisruptionHub we help organisations across the private, public and health sectors to think differently and deliver more

 

Find out more at www.wearefoundry4.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTKLLFFBVLBBBQ

Close

×

RNS Number : 0651W

Croma Security Solutions Group PLC

13 August 2020

 

 

13 August 2020

CROMA SECURITY SOLUTIONS GROUP PLC

("CSSG" or the "Group")

Reinstatement of Dividend and Contract Win

Croma Security Solutions Group Plc, the total security services provider, is pleased to announce the reinstatement of the Company's interim dividend. On 19 March 2020, as a precaution against the potential impact of Covid-19, the Company cancelled the interim dividend announced alongside the Interim Results. Having now completed the financial year to 30 June 2020, it is clear the impact of Covid-19 on Group has been light.

As a consequence, the Company intends to pay an interim dividend of 0.75p per share on 4 September 2020 to shareholders with an ex-dividend date of 20 August 2020 and an associated record date of 21 August 2020.

The Company is also pleased to confirm that post-year end, Croma Vigilant has won a guarding contract from Savills to manage the security for the Edinburgh St James centre. A £1 billion redevelopment, the centre is a major scheme in the heart of Edinburgh and is due to open in Spring 2021. The guarding contract is for 3 years, worth £1.3 million annually and commences from 2 April 2021.

The centre includes retail, commercial and residential buildings and under the new contract, Croma Vigilant will provide a range of its premium guarding services including PROception. Led by ex-policewoman Ruth McGowan, PROception was launched in 2019 and brings the amalgamation of 3 key disciplines: reception, concierge and security, to create the modern front of house professional.

Chairman, Sebastian Morley, said, "At the outbreak of the Covid-19 pandemic in March we took the decision to cancel the dividend until we gained greater visibility on the impact it might have. Pleasingly, the impact has been slight, due in part to the organisation and flexibility of our teams which maintained all services at full strength. Having now completed the financial year, we expect we will deliver a good financial performance and with no borrowings and record levels of cash we are comfortable in re-instating the interim dividend.

The Edinburgh St James centre security contract was a highly competitive tender and as a team we are delighted to have been chosen and believe our premium security services coupled with the range of additional capabilities we are able to provide were instrumental in securing this prestigious contract."

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

For further information contact:

Croma Security Solutions Group plc Sebastian Morley, Chairman	Tel: +44 (0)7768 006 909
WH Ireland Limited (NOMAD and Broker) Mike Coe / Chris Savidge	Tel: +44 (0)207 220 1666
Novella Communications Tim Robertson / Fergus Young	Tel: +44 (0)203 151 7008

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

DIVKXLBFBVLZBBZ

Close

×

RNS Number : 9549V

N4 Pharma PLC

12 August 2020

 

12 August 2020

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

 

 Positive Covid-19 In Vitro Study Results

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that Nuvec® loaded with Coronavirus plasmid has successfully transfected Human Embryonic Kidney ("HEK") cells in vitro and induced an expression of the spike protein in the cells.

 

This successful result is the second stage of the Company's three stage plan for its Covid-19 proof of concept research project being undertaken with Evotec International Gmbh ("Evotec") means that the project will now move into its third stage, being the pre in vivo study to demonstrate expression of the spike protein in target cells in a murine target.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"We are delighted to have achieved in vitro transfection of HEK cells with Nuvec® loaded with coronavirus plasmid. We now move straight to the third stage of our Covid-19 project with our pre in vivo study at Evotec. The global pandemic continues to dominate all of our lives and we are extremely excited to be moving onto the next stage of our Covid-19 project, the successful outcome of which will determine our next work streams in this area and how we might collaborate with appropriate partners interested in any advantage our Nuvec® delivery system may provide. We look forward to providing updates on this project and our other work streams in due course."

 

Clarification note

 

In the Company's announcement of 16 April 2020, it stated the original intention to use murine peripheral blood mononuclear ("PBMC") cells for the in vitro study. However, when working with the PBMCs it was not possible to get a sufficient number to undertake all the experiments. As a result the in vitro work was done using HEK cells as detailed above.

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

 

 

Enquiries:

 

N4 Pharma plc
Nigel Theobald, CEO	Via Scott PR
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP	Tel: +44(0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited	Tel: +44(0)20 3657 0050
Joint Broker
Andy Thacker
Scott PR
Georgia Smith	Tel: +44(0)1477 539 539

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCSFIFEEESSELA

Close